The Journal of Clinical Endocrinology & Metabolism · 2022 · 36 citations · 27 references
MedicineEndocrinologyPharmacologyClinical NutritionDiabetologyMetabolic RegulationAdipose TissueBody CompositionBody Composition ChangesDiabetes ManagementDiabetes MellitusInsulin ResistanceAdipose Tissue DysfunctionBlood Glucose RegulationBody Composition MeasurementBody Fat PercentageHepatic Insulin ResistanceInsulin Resistance AssessmentSkinfold Thickness MeasurementType 2 Diabetes Treatment
CONTEXT: Excess hepatic and pancreatic fat may contribute to hyperglycemia. OBJECTIVE: The objective of this study was to examine the effect of dapagliflozin (an SGLT2 inhibitor) on anthropometric profile, liver, and pancreatic fat in patients with type 2 diabetes mellitus (T2DM). METHODS: This is an observational interventional paired study design without a control group. Patients (n = 30) were given dapagliflozin 10 mg/day (on top of stable dose of metformin and/or sulfonylureas) for 120 days. Changes in anthropometry (circumferences and skinfold thickness), surrogate markers of insulin resistance, body composition, liver, and pancreatic fat (as measured by magnetic resonance imaging (MRI)-derived proton density fat fraction [FF]) were evaluated. RESULTS: After 120 days of treatment with dapagliflozin, a statistically significant reduction in weight, body mass index (BMI), body fat, circumferences, and all skinfold thickness was seen. A statistically significant reduction in blood glucose, glycated hemoglobin A1c, hepatic transaminases, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and postprandial C-peptide was noted, while HOMA-β, postprandial insulin sensitivity, and fasting adiponectin were statistically significantly increased. There was no change in lean body mass. Compared to baseline there was a statistically significant decrease in mean liver FF (from 15.2% to 10.1%, P < .0001) and mean pancreatic FF (from 7.5% to 5.99%, P < .0083). Reduction in liver fat was statistically significant after adjustment for change in body weight. CONCLUSION: Dapagliflozin, after 120 days of use, reduced pancreatic and liver fat and increased insulin sensitivity in Asian Indian patients with T2DM.
27
The utility of radiological imaging in nonalcoholic fatty liver disease
Sherif Saadeh, Zobair M. Younossi, Erick M. Remer et al. · Gastroenterology · 2002 · 2.1K citations
Anoop Misra, Pradeep Chowbey, B. M. Makkar et al. · PubMed · 2009 · 1.2K citations
Jan Bolinder, Östen Ljunggren, Joel Kullberg et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 860 citations
Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson et al. · Diabetologia · 2018 · 387 citations · Full text